Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for AMR Prevention in Kidney Transplant
NCT01399593Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2011
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR), sponsored by Alexion Pharmaceuticals. Started Nov 2011; status: terminated.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01399593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399593.